Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy

Cancer immunotherapy has revolutionized oncology but faces significant challenges including low response rates and lack of effective preclinical models. This review elucidates how patient-derived organoids (PDOs) are emerging as a transformative platform to address these hurdles. We detail sophistic...

Cijeli opis

Bibliografski detalji

Glavni autori:	Dongmei Ni, Junjie Xing, Gengming Niu, Jingjing Qiu, Guiying Wei, Gang Chen, Qinghe Zhou, Xiaolan Yin
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-02-01
Serija:	Frontiers in Cell and Developmental Biology
Teme:	biomarker cancer immunotherapy immune checkpoint inhibitors (ICIs) patient-derived organoids (PDOs) tumor microenvironment (TME)
Online pristup:	https://www.frontiersin.org/articles/10.3389/fcell.2026.1757516/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!